Onclast
Onclast Brand names, Onclast Analogs
Onclast Brand Names Mixture
- No information avaliable
Onclast Chemical_Formula
C4H13NO7P2
Onclast RX_link
http://www.rxlist.com/cgi/generic/alendron.htm
Onclast fda sheet
Onclast msds (material safety sheet)
Onclast Synthesis Reference
M. I. Kabachnik et al., Bull. Acad. Sci. USSR,.27, 374 (1978)
Onclast Molecular Weight
249.096 g/mol
Onclast Melting Point
233 - 235 oC
Onclast H2O Solubility
1mg/L
Onclast State
Solid
Onclast LogP
-3.198
Onclast Dosage Forms
Tablets (6.53, 13.05, 45.68, 52.21 or 91.37 mg of alendronate monosodium salt trihydrate)
Onclast Indication
For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Onclast Pharmacology
Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women.
Onclast Absorption
Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast.
Onclast side effects and Toxicity
Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis."
Onclast Patient Information
Onclast Organisms Affected
Humans and other mammals
